Aurisco to build an Oligonucleotide FlexFactory™ for commercial cGMP production in cooperation with Cytiva

- In future, Aurisco's new commercial manufacturing site in Yangzhou, China is expected to produce up to 200 kilograms of cGMP oligonucleotides each year.
- Through the cooperation with Cytiva, Aurisco will deliver at least 2 new commercial oligonucleotides per year to its global customers, with high quality and efficiency.

Jan 3rd, 2023

On its 25th anniversary, **Aurisco Pharmaceutical**, an innovative pharmaceutical CRDMO (contract research, development and manufacturing organization) is cooperating with **Cytiva**, a global provider of technologies and services in life sciences, to build its first **Oligonucleotide FlexFactory™ platform for commercial cGMP production** in China. Enabled with better speed and efficiency, the new line adds cGMP *capacity to Aurisco's multiple OligoPilot™ units, to* develop and deliver more oligonucleotides and better serve its customers around the world.

From left to right: Peng Zhien, Chairman of Aurisco Pharmaceutical Co., Ltd., Li Jinliang, General Manager of Shanghai Aurisco Biotechnology Co., Ltd., Zhou Yun, Director of Cytiva China Enterprise Solutions, and Yu Lihua, General Manager of Cytiva China.

The Oligo FlexFactory™ platform is the first of three planned commercial manufacturing lines of Aurisco for its Yangzhou site in the East of China, to increase capacity to produce up to 200 kilograms of cGMP oligonucleotides every year.

Oligonucleotides are synthetic strands of DNA or RNA that can be used as therapies, diagnostics by binding to a target gene or protein sequence. Oligonucleotide therapeutics, including siRNA (small interfering RNA) and ASO (antisense oligonucleotide), hold promise in treating cancers, Parkinson's diseases, and various other conditions. The global oligonucleotide synthesis market is expected to reach USD 16.7 billion by 2027, according to Research and Markets[1].

Aerial view of Aurisco's Yangzhou site plan

Mr. Peng Zhien, the Chairman of Aurisco says: "Aurisco is committed into continuous technological innovation that will help our customers deliver better and safer medicines to patients around the world. I believe the cooperation with Cytiva will facilitate our mission by bringing better speed and efficiency to the commercial production of oligonucleotides."

Mrs. Yu Lihua, General Manager of Cytiva China explained: "We have witnessed Aurisco's rapid development from small tests and pilot production of small nucleic acids to commercial production. In the future, the two sides will continue to deepen cooperation to continuously improve the safety and efficiency of drug research and development and production, enabling innovative drugs to benefit more patients."

[1]Research and Markets, November 2022. https://www.researchandmarkets.com/reports/5312415/global-oligonucleotide-synthesis-market-by.

During this cooperation, Cytiva will offer a comprehensive enterprise solution to Aurisco. It includes an Oligo FlexFactory™ GMP platform and various technical and service support, such as talent training, process design of the manufacturing site, as well as life-cycle project management.

Li Jinliang, GM of Aurisco's Biotech CRDMO and Yu Lihua, GM of Cytiva China visiting Aurisco's R&D labs in Shanghai. Cytiva and Aurisco cooperated to build a flexible factory production line for small nucleic acid in Yangzhou to accelerate the commercial development of small nucleic acid drugs.

It's not the first time Aurisco has collaborated with Cytiva. Previously, with the support of Cytiva's products and service, Aurisco has launched its oligonucleotide CRDMO (contract research, Development and Manufacturing Organization) services of laboratory and pilot scales in Shanghai.

In the future, Aurisco and Cytiva will look into more cooperative opportunities at the Yangzhou commercial manufacturing site, accelerating the delivery of life-changing medicines to more patients.

About Aurisco

Established in 1998, Aurisco is an innovative pharmaceutical company engaged in research, development, manufacturing and marketing of complex APIs, formulations and CRO/CDMO services in new modalities, such as oligonucleotides, peptides and GalNAc conjugation. Listed in the Shanghai Stock Exchange, the company has USFDA, EU GMP and NMPA inspected sites and multiple R&D centers. Aurisco has been deeply involved in the pharmaceutical industry for 25 years and commits itself to sustainability and continuous technological innovation. Today the company is playing a leading role in China in the field of complex synthesis, synthetic biology,

photochemistry, etc., and has become a long-term partner of well-known pharmaceutical companies worldwide. Complete quality system, sufficient production capacity and global sales network enable the company to provide high-quality products and efficient service to our customers around the world.

About Cytiva

Cytiva is a global life sciences pioneer, with nearly 10,000 employees in more than 40 countries and territories, committed to advancing breakthrough technologies to accelerate extraordinary therapies. As a trusted partner, Cytiva actively works with researchers, biotechnology developers and manufacturers in academic and transformative medicine. Focusing on research in biopharmaceuticals, cell and gene therapy and a range of innovative technologies represented by mRNA, increasing the capacity, speed, efficiency and flexibility of research and development of drugs and bioprocesses, developing and producing revolutionary drugs and therapies for the benefit of patients around the world.

Enquiries and Media Contact: crdmo@auriscopharma.com